相似文献
1
Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues.
Br J Clin Pharmacol. 2009 Apr;67(4):475-7. doi: 10.1111/j.1365-2125.2009.03374.x.
2
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Clin Pharmacokinet. 2004;43(15):1089-115. doi: 10.2165/00003088-200443150-00003.
3
Endothelin antagonism with bosentan: current status and future perspectives.
Cardiovasc Drug Rev. 2002 Winter;20(1):1-18. doi: 10.1111/j.1527-3466.2002.tb00078.x.
4
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
J Clin Pharmacol. 2008 May;48(5):610-8. doi: 10.1177/0091270008315315. Epub 2008 Feb 27.
5
Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.
Clin Pharmacokinet. 2003;42(3):293-301. doi: 10.2165/00003088-200342030-00004.
6
No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs.
Acta Anaesthesiol Scand. 2003 Feb;47(2):200-7. doi: 10.1034/j.1399-6576.2003.00019.x.
7
Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
J Clin Pharmacol. 2012 Dec;52(12):1784-805. doi: 10.1177/0091270011423662. Epub 2011 Dec 28.
8
Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Int J Clin Pharmacol Ther. 2002 Jul;40(7):310-6. doi: 10.5414/cpp40310.
9
Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
J Clin Pharmacol. 2002 Mar;42(3):283-9. doi: 10.1177/00912700222011300.
10
Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
J Clin Pharmacol. 1999 Jul;39(7):703-14. doi: 10.1177/00912709922008344.
本文引用的文献
1
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Eur Respir J. 2008 Jul;32(1):198-209. doi: 10.1183/09031936.00124007.
2
Ambrisentan for the management of pulmonary arterial hypertension.
Clin Ther. 2008 May;30(5):825-33. doi: 10.1016/j.clinthera.2008.05.005.
3
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
J Clin Pharmacol. 2008 May;48(5):610-8. doi: 10.1177/0091270008315315. Epub 2008 Feb 27.
4
Sildenafil: a review of its use in pulmonary arterial hypertension.
Drugs. 2008;68(3):383-97. doi: 10.2165/00003495-200868030-00009.
5
Endothelin receptor antagonists in pulmonary arterial hypertension.
Eur Respir J. 2008 Feb;31(2):407-15. doi: 10.1183/09031936.00078207.
6
Review of bosentan in the management of pulmonary arterial hypertension.
Vasc Health Risk Manag. 2007;3(6):887-900.
7
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Eur J Clin Pharmacol. 2008 Jan;64(1):43-50. doi: 10.1007/s00228-007-0408-z. Epub 2007 Nov 27.
8
Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
Lupus. 2007;16(11):901-3. doi: 10.1177/0961203307083367.
9
A review of pulmonary arterial hypertension: role of ambrisentan.
Vasc Health Risk Manag. 2007;3(1):11-22.
10
Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Drug Metab Dispos. 2007 Aug;35(8):1400-7. doi: 10.1124/dmd.106.013615. Epub 2007 May 11.
Zotero 插件